Company sells 21,958,302 ordinary shares at $0.57 apiece to investors
By Devika Patel
Knoxville, Tenn., Sept. 30 - Celsus Therapeutics said it took in $12.52 million in a private placement of stock. The deal priced for $12.5 million Sept. 19.
The company sold 21,958,302 ordinary shares at $0.57 apiece. The per-share price represents an 85.75% discount to the Sept. 18 closing share price of $4.00.
MTS Securities, LLC was the lead placement agent and Oppenheimer and Co., LLC was the co-placement agent.
Proceeds will be used to advance the company's lead non-steroidal anti-inflammatory dermatology asset, MRX-6, through an Investigational New Drug application in the United States and for clinical studies.
"We are excited to advance the development of MRX-6 into several clinical indications," chief executive officer Gur Roshwalb said in a press release. "We believe that a safe and effective non-steroidal anti-inflammatory cream serves an important and unmet clinical need and will further validate our novel multi-functional anti-inflammatory drug platform. With our current burn rate, we expect this financing to give us a cash runway into 2015."
The New York biotechnology company is developing a new class of non-steroidal, synthetic anti-inflammatory drugs.
Issuer: | Celsus Therapeutics
|
Issue: | Ordinary stock
|
Amount: | $12,516,232
|
Shares: | 21,958,302
|
Price: | $0.57
|
Warrants: | No
|
Agents: | MTS Securities, LLC (lead) and Oppenheimer and Co., LLC (co-placement agent)
|
Pricing date: | Sept. 19
|
Settlement date: | Sept. 30
|
Stock symbol: | OTCBB: CLSXY
|
Stock price: | $4.00 at close Sept. 18
|
Market capitalization: | $28.08 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.